FLT3-ITD classifier predicts clinical outcome. Kaplan-Meier survival analysis of NK-AML independent test set for (A) FLT3-ITD mutation and remission duration, (B) PAM-predicted FLT3-ITD mutation and remission duration, (C) FLT3-ITD mutation and disease-free survival, (D) PAM-predicted FLT3-ITD mutation and disease-free survival, (E) FLT3-ITD mutation and overall survival, and (F) PAM-predicted FLT3-ITD mutation and overall survival. For the PAM prediction groups, samples not evaluated for FLT3-ITD status were excluded. P values (log rank test) are indicated.